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Abstract: Colorectal adenomas are precursor lesions of colorectal adenocarcinoma. The transition
from adenoma to carcinoma in patients with colorectal cancer (CRC) has been associated with an
accumulation of genetic aberrations. However, criteria that can screen adenoma progression to
adenocarcinoma are still lacking. This present study is the first attempt to identify genetic aberrations,
such as the somatic mutations, copy number variations (CNVs), and high-frequency mutated genes,
found in Thai patients. In this study, we identified the genomic abnormality of two sample groups.
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In the first group, five cases matched normal-colorectal adenoma-colorectal adenocarcinoma. In the
second group, six cases matched normal-colorectal adenomas. For both groups, whole-exome
sequencing was performed. We compared the genetic aberration of the two sample groups. In both
normal tissues compared with colorectal adenoma and colorectal adenocarcinoma analyses, somatic
mutations were observed in the tumor suppressor gene APC (Adenomatous polyposis coli) in
eight out of ten patients. In the group of normal tissue comparison with colorectal adenoma
tissue, somatic mutations were also detected in Catenin Beta 1 (CTNNB1), Family With Sequence
Similarity 123B (FAM123B), F-Box And WD Repeat Domain Containing 7 (FBXW7), Sex-Determining
Region Y-Box 9 (SOX9), Low-Density Lipoprotein Receptor-Related Protein 5 (LRP5), Frizzled Class
Receptor 10 (FZD10), and AT-Rich Interaction Domain 1A (ARID1A) genes, which are involved in
the Wingless-related integration site (Wnt) signaling pathway. In the normal tissue comparison
with colorectal adenocarcinoma tissue, Kirsten retrovirus-associated DNA sequences (KRAS), Tumor
Protein 53 (TP53), and Ataxia-Telangiectasia Mutated (ATM) genes are found in the receptor tyrosine
kinase-RAS (RTK–RAS) signaling pathway and p53 signaling pathway, respectively. These results
suggest that APC and TP53 may act as a potential screening marker for colorectal adenoma and
early-stage CRC. This preliminary study may help identify patients with adenoma and early-stage
CRC and may aid in establishing prevention and surveillance strategies to reduce the incidence
of CRC.
Keywords: somatic mutation; colorectal adenoma; early-stage colorectal adenocarcinoma; screen marker
1. Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide, with increasing numbers of
estimated new cases in both males and females [1]. Approximately 0.45% of the population in the
USA is diagnosed with CRC [2,3], which is the third most common cancer in the USA. CRC is the
second most incident cancer in Thailand. The five-year survival rates of CRC in the early-stage and
advanced-stage in males and females are approximately 63%–92% and 11%–89%, respectively [4].
It has been reported that the majority of diagnosed CRC patients in Thailand have advanced-stage
cancer (70.80%), with an overall survival rate of 5% [4,5]. Previous studies reported that new CRC
cases in Thailand increased by 8.68% and 6.86% in males and females, respectively [5,6]. These results
indicated that an effective screening program is necessary for the prevention of CRC in the Thai
population [5,7,8]. Therefore, accumulation for mutation information related to CRC in the Thai
population by screening for colorectal adenoma, which is the precursor lesion for CRC, and diagnosis
of early-stage CRC are both very important for CRC prevention [9,10].
The development of CRC is a complex and heterogeneous process. The transformation of normal
colon tissue to a CRC sequence is known to be caused by several genetic aberrations, such as mutations
that inactivate tumor suppressor gene function, chromosomal instability, and DNA methylation
alteration [11–14]. The progression from normal tissue to colorectal cancer can be classified into two
pathways, which are the traditional pathway and alternative pathway. As for the traditional pathway,
the normal cell developed tubular adenomas followed by the development of colorectal cancer through
the Wnt signaling pathway, mitogen-activated protein kinases (MAPK) pathway, phosphoinositide
3-kinase (PI3K) signaling pathway, transforming growth factor-β (TGFβ) signaling pathway, and p53
signaling pathway. The alternative pathway involves sessile serrated polyps and their progression to
colorectal cancer by the same sequential pathway as the traditional pathway [11]. Recent advances
in DNA sequencing technology have enabled a better understanding of the molecular basis of CRC
pathogenesis [13,15–18]. Comparison of the genetic profile between normal, colorectal adenoma,
and CRC in Chinese CRC patients by exome capture sequencing identified somatic gene mutations
involved in the Wnt signaling pathway, cell adhesion, and ubiquitin-mediated proteolysis pathway [19].
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In examining the progression of normal cells to colorectal adenoma and adenocarcinoma and searching
for potential molecular markers, studies have identified differences in driver mutations in sessile
serrated adenoma compared with conventional adenoma [20,21]. However, results from a study of
African American CRC patients showed different patterns of somatic gene mutations compared with
mutations derived from The Cancer Genome Atlas (TCGA) data [22].
A recent attempt to establish a screening protocol in the Thai population during July 2009–June
2010 examined new potential CRC screening methods in 1404 healthy volunteers using a fecal occult
blood test (FOBT) and fecal immunochemical tests (FITs). The obtained results were compared with
the screening results by colonoscopy. The study suggested the integration of colonoscopy into the
national screening approach for the detection of early-stage CRC [8]. Although the gold standard of
CRC early detection is a colonoscopy, this strategy is not cost-effective at the population screening
level [23] and may be prone to causing infection by pathogenic bacteria and virus, such as hepatitis B
and C, prion disease, Salmonella spp. and HIV [24]. A non-invasive approach can eliminate the risk
of infectious disease during the examination. However, methods such as whole-genome sequencing
are still expensive. Thus, a non-invasive screening technique with high sensitivity and specificity for
early-stage colorectal adenoma and CRC is required [25–27].
In general, the treatment of colorectal cancer is chemotherapy, radiotherapy, adjuvant therapy,
and surgery [11]. The response rate of the first-line drug which was used in the metastasis stage is
20% [28]. Moreover, the second-line drug which targeted the RAS wild-type has a higher response
rate but the side effects may be harmful to patients and affect their quality of life [28]. Recent studies
revealed the mechanism of the new therapeutic targets that are involved in cell proliferation, tumor
progression, apoptosis, drug resistance, and autophagy [29–35]. Inhibition of TGF-β1, FAHFA, which
protects tumors from apoptosis, resulting in an enhanced CRC treatment response [31,34]. In addition,
the reduction of drug resistance, proliferation, and cancer progression due to silence expression and
function of MAGL, HuR, CDC6, and TPC1 represent an innovative therapeutic approach [29,30,32,35].
Moreover, the five-year survival rate of early stage of colorectal cancer is 90% but reduces to 14%–71%
in advanced stage [36]. It was found that only 39% of CRC patients were detected in early-stage
CRC. This information indicated that increased efficiency of early screening may possibly increase the
five-year survival rate and decrease the mortality rate. Therefore, a precise early detection process
is vital.
The aim of this study was to identify the genetic abnormalities in genes associated with a high
susceptibility of CRC from matched normal, colorectal adenoma, and CRC samples of Thai CRC
patients using exome sequencing analysis for potential application as a noninvasive screening marker,
such as the amplification of specific genes from stool DNA followed by mutation detection for early
screening of precancerous and early-stage CRC.
2. Results
2.1. Identification of Gene with Somatic Mutations in Normal-Colorectal Adenoma and Normal-CRC in
CRC Patients
Genes with somatic mutations are mutations that occur in cancer cells and not healthy cells [37],
and represent one of the main factors that lead to cancer [38]. A total of 2044 genes with somatic
mutations were identified in matched normal-colorectal adenoma, which show enrichment in the
calcium signaling pathway, focal adhesion pathway, and proteoglycan in the cancer pathway. A total
of 1045 genes with the somatic mutation were classified in matched normal-CRC with enrichment
in the glutamatergic synapse pathway, phospholipase D signaling pathway, and protein digestion
and absorption pathway. The intersection of a gene with somatic mutations between the matched
normal-colorectal adenoma and matched normal-CRC were enriched in the focal adhesion pathway,
protein digestion and absorption pathway, and PI3K-Alt signaling pathway (Figure 1).
Cancers 2019, 11, 977 4 of 17
Cancers 2019, 11, x FOR PEER REVIEW 4 of 17 
 
absorption pathway. The intersection of a gene with somatic mutations between the matched normal-
colorectal adenoma and matched normal-CRC were enriched in the focal adhesion pathway, protein 
digestion and absorption pathway, and PI3K-Alt signaling pathway (Figure 1). 
 
(a) 
 
(b) 
 
(c) 
Figure 1. Enriched genes of (a) normal-colorectal adenoma, (b) normal colorectal cancer (CRC), and 
(c) the intersection of normal-colorectal adenoma and normal-CRC. 
To determine whether the genes with somatic mutations identified from normal-colorectal 
adenoma and normal-CRC have been reported in other population. The genes with somatic 
mutations identified from normal-colorectal adenoma and normal-CRC were compared with those 
of TCGA, African American, and Chinese CRC data. The result revealed different identified genes in 
the three groups, except APC genes [22]. The African American CRC patient study showed somatic 
mutations in genes APC, KRAS, Fc Receptor Like 5 (FCRL5), obscurin, cytoskeletal calmodulin and 
titin-interacting RhoGEF (OBSCN), Retinitis Pigmentosa 1 Like 1 (RP1L1), Dynein Axonemal Heavy 
Chain 17 (DNAH17), Zinc Finger Protein 568 (ZNF568), and Calcium Voltage-Gated Channel Subunit 
Alpha1 C (CACNA1C) [22]. Based on the TCGA data, the identification of a somatic alteration in CRC 
was performed by many omics scales within 276 samples. The TCGA analysis result identified gene 
mutations in APC, TP53, SOX9, KRAS, PIK3CA, TTN, FBXW7, and SMAD4 [13]. The genes with the 
somatic mutation were compared with TCGA data [13,22] (Figure 2). We found that the identified 
genes with the somatic mutation from TCGA data showed a minor overlap with those identified from 
normal-colorectal adenoma and normal-CRC samples. The Chinese study performed whole-exome 
sequencing for both matched normal-colorectal adenoma and matched normal-CRC to identify the 
genes with somatic mutations. The matched normal-colorectal adenoma result showed the genes 
with somatic mutations in APC, AMA3, OR6X1, NMBR, EFR3A, RBFOX1, CDH20, BIRC6, KRT84, 
. Enriched genes of (a) normal-colorect l adenoma, (b) norma colore tal cancer (CRC),
and (c) th intersectio f normal-colorectal adenoma and normal-CRC.
To deter ine hether the genes ith so atic utations identified fro nor al-colorectal
adeno a and normal-CRC have been reported in other population. The genes with somatic mutations
identified from normal-colorectal adenoma and normal-CRC were compared with those of TCGA,
African American, and Chinese RC data. The result revealed different identified genes in the
three groups, except APC genes [22]. The African American CRC patient study sho e so atic
tations in genes , S, Fc ece tor ike 5 (F L5), obsc rin, cytoskeletal cal o lin an
titin-interacting ho F ( S ), etinitis ig entosa 1 ike 1 ( 1L1), ynein xone al eavy
hain 17 ( 17), inc Finger rotein 568 ( F568), an alci oltage- ate hannel S b nit
l ha1 ( 1 ) [22]. ase on the ata, the i entification of a so atic alteration in
as erfor e by a y o ics scales it i 276 sa les. e a alysis res lt i e tifie ge e
tatio s i , 53, S 9, S, I 3 , , F 7, a S 4 [13]. e ge es it t e
so atic tatio ere co are it ata [13,22] (Fig re 2). e fo t at t e i e tifie
ge es it t e so atic tatio fro ata s o e a i or overla it t ose i e tifie fro
or al-colorectal a e o a a or al- sa les. e i ese st y erfor e ole-exo e
se e ci f r t atc e r al-c l rectal a e a a atc e r al- t i e tif t e
e es ith somatic mutations. The matched normal-colorectal adenoma result showed the genes with
somatic utations in APC, AMA3, OR6X1, NMBR, EFR3A, RBFOX1, CDH20, BIRC6, KRT84, SLC15A3,
FTHL17, and GLCCI1. The matched normal-CRC revealed the genes with somatic mutation in APC,
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FBXW7, FLT4, GSK3A, ZFP64, NRXN3, TGM7, GRIK1, KIF25, DTL, GNAL, ATF2, OR51E2, CUX1,
PPAP2C, CORO1A, OR13J1, KRTAP19-7, POU4F3, PPP1R3C, NARS2, NFATC2, FAM109A, FAM54A,
TFR2, ZNF781, RRP8, ZFP36L2, KRT31, RYR1, KIAA1409, NRG1, PGM1, ALPK1, FAM181A, FCRL3, and
SDK1 [19]. Colorectal adenoma samples of p4, p6, p7, p10, p11, p12 exhibit mutations in APC, while p4,
p13, and p14 show mutations in CTNNB1. p6 and p11 show mutations in FAM123B. In addition, CRC
samples of p5, p10, and p14 reveal the mutation in APC. As for CRC samples of p4, p5, and p10, the
mutations of the SOX9 gene were found. While CRC of p2 and p10 exhibit mutations in the TP53 gene
(Table S2). Finally, mutations in the FBXW7 and KRAS genes are identified in CRC of p14 (Figure 2).
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Figure 2. Comparison of the alter gene between The Cancer Genome Atlas (TCGA) and Thai patients.
The rows show the list of patients. The columns show the list of gene names.
addition, comparison of the g nes with somatic mutations in the normal-CRC, normal-col rectal
adenom groups, the Chinese study, the TCGA data, and frican American CRC patients demons rated
that SOX9 and TP53 genes were common g nes in the TCGA and Thai normal-CRC data, whereas
the CTNNB1 gene was a common gene in the Thai normal-colorectal denoma nd TCGA data.
Moreover, the FBXW7 gene was a common gene in Chinese normal-CRC and TCGA (Figure 3) (Table 1).
Interestingly, APC was found as a common gene in the f ur groups.
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Table 1. Genes with somatic mutations identified in this study that overlap with TCGA, Chinese, and African American CRC patient data.
Patient Chr Start Stop Reference Alternative Gene Mutation Exonic Function Protein Change Known
p5t 5 112174631 112174631 C T APC SNV Stop gain p.Arg1114Ter rs121913331, COSM13125
p10t 5 112151185 112151185 T G APC SNV Splice Region variant -
p14t 5 112155021 112155022 TG - APC deletion Frame shift variant p.Met431ArgfsTer12
p4low 5 112175639 112175639 C T APC SNV Stop gain p.Arg1450Ter rs121913332, COSM13127
p6low 5 112174249 112174249 T A APC SNV Stop gain p.Tyr986Ter
p7low 5 112174129 112174129 A - APC deletion Frame shift variant p.Cys947ValfsTer8
p7low 5 112175255 112175255 G T APC SNV Stop gain p.Glu1322Ter
p10low 5 112175390 112175391 - A APC Insertion Frame shift variant p.Thr1368AspfsTer7
p11low 5 112175639 112175639 C T APC SNV Stop gain p.Arg1450Ter rs121913332, COSM13127
p12low 5 112155031 112155032 - A APC Insertion Frame shift variant p.Asn436LysfsTer8
p2t 17 7578510 7578510 G - TP53 Deletion Frame shift variant p.C141Afs*29 COSM69019
p10t 17 7576889 7576890 - T TP53 Insertion Frame shift variant p.K320Efs*17
p4t 17 70119862 70119863 - TTCGA SOX9 Insertion Missense mutation p.V291Sfs*94
p5t 17 70119855 70119856 - CGAGA SOX9 Insertion Frame shift variant p.F289Rfs*96
p10t 17 70118889 70118889 A A SOX9 SNV Frame shift variant p.F154Y
p4low 3 41274898 41274898 G C CTNNB1 SNV Missense mutation p.Trp383Ser
p13low 3 41266124 41266124 A G CTNNB1 SNV Missense mutation p.Thr41Ala rs121913412
p14low 3 41266097 41266097 G A CTNNB1 SNV Missense mutation p.Asp32Asn rs28931588
p14low 4 153258983 153258983 G A FBXW7 SNV Stop gain p.Arg278Ter
p14t 4 153268102 153268102 C - FBXW7 Deletion Frame shift variant p.Glu236AsnfsTer3
Chr = Chromosome.
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2.2. Copy Number Variation (CNVs)
CNVs are structural variations due to chromosome alterations, including duplication or deletion
of regions in the genome, that lead to carcinogenesis in tumor patients [39,40]. Early-stage CRC can be
detected by the gain of chromosomes 8q, 13, and 20q and loss of chromosomes 8p, 17p, and 18q [41].
Other studies have identified CNVs using plasma and CRC tissues. The finding exhibited the CNVs
gain chromosome 20, position 20q12, and the CNVs loss in chromosome 8, position 8p23.1 to 8p23.2 [42].
Therefore, the identification of CNVs may yield more potential markers for further investigation. Here,
we identified CNVs from matched normal-colorectal adenoma and normal-CRC only in the autosome.
The results revealed the gain of chromosome 20 in four patients (Figure 4). These findings suggest that
the gain of chromosome 20 in, for example, the BCL2L1, TPX2, SRC, AURKA, and GNAS genes [43]
may be a potential marker for the detection of early-stage CRC (Table S1).
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2.3. The Analysis of Enriched Genes in Normal-Colorectal Adenoma and Normal-CRC Groups
Since colorectal cancer velopment is involved with sev ral sign ling pathways. The analysis
of enriched genes provides more information and a b tter understandi g of th colorectal cancer
developme t proc s. The identified soma ic mutation genes in normal-col rectal adenoma are
enriched in the calcium signaling pathway, focal adhesion, protein digestion, proteoglycans in cancer,
and the extracellular matrix (ECM)-receptor pathway. The somatic mutation genes in normal-CRC
are enriched in the glutamatergic synapse, phospholipase D signaling pathway, protein digestion
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and absorption, taste transduction, glioma, ECM-receptor interaction and focal adhesion pathway
(Figure 1). The focal adhesion and ECM-receptor pathways play a key role in cancer progression,
migration, proliferation, survival, and apoptosis of tumor cells [44,45].
2.4. Candidate Genes with Driver Mutation in Normal-Colorectal Adenoma and Normal-CRC Groups
Candidate genes with driver mutations are genes that participate in the abnormality of cell growth
in cancer cells but are not involved in carcinogenesis [38]. It appears that the individual who presents
genes with driver mutations may have a greater chance of developing colon cancer. Therefore, the
identification of genes with driver mutations in colorectal adenoma and early-stage CRC may help to
prevent CRC and improve the survival rate and the quality of life of CRC patients. Our results showed
that APC, CTNNB1, IGF1, and KLF5 (Figure 4) were frequently mutated in normal-colorectal adenoma.
The result shows four stop gains and three frameshift variants in the APC gene. The CTNNB1 gene
contained three missense variants, while IGF1 and KLF5 genes are missense variants (Table S3).
The normal-CRC showed mutations in APC, TP53, SOX9, TOPORS, LSR, CALM2, SHISA4, RSPO2,
and SYF2 (Figure 5).
The APC genes contain one stop gain, one frameshift variant, and one splice region variant.
The two frameshift variants are detected in TP53 gene. The SOX9 gene contains one missense variant
and two frameshift variants. The TOPORS gene shows one stop gain and one frameshift variant.
One missense and frameshift variant are found in the LSR gene. The CALM2 gene shows only one
splicing region variant. The SHISA4 gene carries in-frame deletion. The RSPO2 gene includes two
splice region variants. The SYF2 gene consists of one frameshift variant (Table S3).
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3. Discussion
In the last thirty years, the global pattern of incidence and ortality trends of CRC have been
divided into three groups: (1) increase of both incidence and ortality, (2) increase in incidence but
decrease in ortality, and (3) decrease of both incidence and ortality [46]. The reduction of the
ortality rate in groups 2 and 3 is better due to better standard treat ent and early detection of
colorectal adeno a and CRC. It is suggested that i proved screening ethods ay increase the
incidence rate, subsequently reducing the ortality rate in the long-ter [46–53].
The progression of nor al epithelial cells to CRC involves ultiple gene utations ithin
several signaling path ays, such as the nt signaling path ay, APK signaling path ay, PI3K
signaling path ay, TGFβ signaling path ay, and p53 signaling path ay [11]. hile APC, CTNNB1,
LSR, TOPORS, KLF5, IGF1 and SOX9 are related to Wnt signaling pathways, KRAS and BRAF are
involved in RAS signaling pathways [54–60]. This indicates that the abnormalities of proliferative
pathways may crucial in early colorectal cancer development. Additionally, the defects of tumor
suppressor genes such as ATM and TP53 of the P53 signaling pathways are also at the pivot point of
the colorectal tumorigenesis [61,62]. In addition, the CALM2, SHISA4, RSPO2, and SYF2 contributed
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to cell proliferation [63–67]. However, the role of these genes in the cancer development mechanism
has not been elucidated.
Here, we identified mutated genes with somatic mutations in adenoma and CRC samples compared
with matched normal samples that are involved in important signaling pathways, including the Wnt
and p53 signaling pathways. We identified genes with somatic mutations in the normal-colorectal
adenoma samples, APC, CTNNB1, LRP5, FBXW7, and ATM (Figure 2), which overlapped with the
TCGA data. Interestingly, the position c.4348C>T (p.R1450*) of the APC gene was found in 2 out of
11 patients in the matched normal-colorectal adenoma tissue. The point mutation was reported as
the most common mutation of CRC in previous studies from Tunisia and Iran [68,69]. Moreover, this
mutation position was identified as the most frequently mutated position in the colorectal adenoma
studied from the United Kingdom, Czech Republic, and the Netherlands also [70]. We also identified
genes with somatic mutations in normal-CRC samples, APC, FBXW7, SOX9, KRAS, and TP53 (Figure 2),
that overlapped with the TCGA data analysis. All of the identified genes in the present study are the
members of the Wnt, p53, and RTK–RAS signaling pathways. The exome sequences obtained from the
formalin-fixed, paraffin-embedded tissues of the matched normal-colorectal adenoma and normal-CRC
revealed 99.85% coverage in the target region. Analysis of high-frequency mutated genes showed 12
known gene mutations in colon cancer-associated pathways, including APC, TP53, SOX9, TOPORS,
IGF1, KLF5, LSR, CALM2, CTNNB1, RSPO2, SYF2, and SHISA4. The normal-colorectal adenoma
somatic mutation analysis identified mutations in two key genes, APC and CTNNB1, which are known
to be involved in the Wnt signaling pathway. IGF1 contributes to the cell cycle progression and inhibits
the apoptosis pathway [71]; IGF1 also promotes cell growth in CRC by activating the VEGF gene and,
therefore, supports cancer progression of human colon cancer cells [72]. In addition, KLF5 has been
reported as an oncogene that suppresses cancer cell growth and is involved in tumor progression in
CRC mouse models [73–76] (Figure 4). Moreover, a recent study reports that the somatic mutation
c.910C>A (p.P304T) position of KLF5 was reported as the hotspot of mutations in the phosphor–degron
domain, which promotes cancer cell proliferation [58].
Based on our finding, the normal-CRC showed the candidate genes, including APC, TP53, SOX9,
TOPORS, LSR, CALM2, SHISA4, RSPO2, FBXW7, and SYF2. The APC, SOX9, SHISA4, and RSPO2
genes are members of the Wnt signaling pathway [11,65,74,77,78] (Figure 5). The SOX9 gene is
overexpressed in both colorectal adenoma and CRC samples compared with normal tissues by 2- and
3.5-fold, respectively [79,80]. SOX9 is not only the downstream regulator and effector of the Wnt
signaling pathway but also increases cell proliferation and transformation [80].
Gene function analysis revealed that genes were predominantly enriched in the ECM-receptor
interaction and focal adhesion pathways. Integrins directly interact with the components of ECM
and contribute to cell motility and invasion. Studies have demonstrated the crucial role of integrins
in regulating tumor cell progression and metastasis by increasing tumor cell migration, invasion,
proliferation, and survival. Integrin-mediated migration requires focal adhesion kinase (FAK)-Src
family kinase (SFK) signaling [44], which are the main kinases in focal adhesion signaling, followed
by recruitment of the proteins necessary for focal adhesion development. Tumor cells display highly
altered focal adhesion dynamics that may emulate the development and progression of cancer [45].
Wnt/B-catenin is an important signaling cascade involved in both colorectal development and
carcinogenesis [81]. The mutations in this pathway are involved in the first step of progress from
normal to colorectal adenoma. [82]. Mutation in the p53 signaling pathway is closely associated with
the progression of CRC [11]. APC is a tumor suppressor gene and has many functions that affect the
progression of cancer cells, such as proliferation, migration, cytoskeletal maintenance, and chromosome
instability [83,84]. The TP53 gene plays an important function in either cell proliferation or trigger
senescence and apoptosis [85]. Evidence for the roles of APC, TP53, and KRAS as early driver genes
has been demonstrated in several reports [62,86]. Mutated APC, TP53, and KRAS have been identified
in colon adenoma as well as in CRC [62,86]. Our results suggest that the gene set identified in the Wnt,
p53, and RTK–RAS signaling pathways might be used as a candidate precancerous and early-stage
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screening marker for CRC. However, it could not be concluded that the genes with driver mutations
promote the tumorigenesis because, after surgical resection, none of the patients developed colorectal
cancer (the median follow-up period was 6.5 years).
Previous studies showed the gain of chromosome 20 in CRC patients and demonstrated its use
as a marker to detect early-stage CRC [41,42]. Our results in Thai CRC patients revealed a gain
of chromosome 20 in four out of five samples, in agreement with the previous reports (Figure 4).
This suggests that the gain of chromosome 20 in CRC patients could act as a marker for the early
detection of CRC.
4. Materials and Methods
Here, we identified variants, somatic mutation genes, high-frequency mutated genes, gene list
enrichment, and copy number variations (CNVs) following the study flow shown in Figure S1.
4.1. Samples
The patients included in this study were in a CRC screening cohort that underwent colonoscopy
at Chulabhorn hospital between July 2009 and June 2010. The present study was approved by
the Human Research Ethical Committee of the Chulabhorn Research Institute. All formalin-fixed,
paraffin-embedded specimens of colorectal adenoma and adenocarcinoma were obtained from the
pathology laboratory unit. The specimens were reviewed by the pathologist to confirm the diagnosis and
distinguish between low-grade dysplasia and high-grade dysplasia before performing microdissection.
A total of 1500 participants were enrolled in the project (Figure 6). The exclusion criteria included
age, poor medical problem control, and the inability to be followed during the study, resulting in
1404 participants [8]. The inclusion criteria were set as (i) colorectal adenoma tissue classified as a
high-risk grade, either villous or tubulovillous or sessile serrated polyps, (ii) colorectal adenoma size
greater or equal to 1 cm, (iii) the number of colorectal adenomas greater than or equal to 3 polyps,
and (iv) matched normal and CRC samples were available. In total, a small cohort of the 5 cases with
matched normal and colorectal adenoma tissue and CRC tissue, as well as the 6 cases with matched
normal and colorectal adenoma tissue samples, were selected. Patients p2, p4, p6, p7, p10, p11, p12,
p13, and p14 had tubular adenoma, while patients p5 and p13_2 had serrated adenoma (Table 2).
Among the cases with CRC samples, p4, p5, p10, and p14 showed stage IIA CRC and p2 showed stage I
CRC. The locations of most of the specimens were on the left side of the colon, except for the specimen
for p10, which was located on the right side.
Table 2. The clinical information of colorectal adenomatous and CRC patient.
Patient Gender/Age Adenoma Adenocarcinoma Stage/TNM LVI Location
p2 M/65 TA A I/pT2N0M0 Y L
p4 M/55 TA A IIA/pT3N0M0 N L
p5 F/58 SA A IIA/pT3N0M0 Y L
p6 M/64 TA - - N L
p7 M/58 TA - - N L
p10 F/56 TA A IIA/pT3N0M0 Y R
p11 M/58 TA - - N L
p12 M/60 TA - - N L
p13 M/61 TA - - N L
p13_2 M/61 SA - - N L
p14 M/66 TA A IIA/pT3N0M0 N L
M = male, F = female, TA = Tubular adenoma, SA = Serrated adenoma, A = adenocarcinoma, L = left, R = right,
LVI = Lymphovascular Invasion, Y = Yes, N = No.
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4.2. DNA Extraction and Library Preparation
Genomic DNA was extracted from formalin-fixed, paraffin-embedded tissue using a QIAmp
DNA Microkit (Qiagen, Hilden, Germany). The DNA quality and quantity were determined using
a NanoDrop ND-1000 (Nanodrop Technology, Wilmington, DE, USA) and Qubit® 2.0 Fluorometer
(Life Technologies, Carlsbad, CA, USA), respectively. Exome sequencing was performed by Macrogen
(Seoul, Korea) using the SureSelect human all exon kit V4+UTR (Agilent Technologies, Santa Clara, CA,
USA), and the exome library of 101 bases paired reads were sequenced using the Illumina HiSeq2000
(Illumina, San Diego, CA, USA) at 100 reads coverage.
4.3. Whole-Exome Analysis
To identify point mutations and somatic mutations, the raw FASTQ files were trimmed by
trimmomatic [87], then aligned to a human reference genome (GRCh37) by Burrows-Wheeler Alignment
Tool (BWA) [88]; duplicate reads were removed by Picard tools [89] and variant calling was performed
by the Genome Analysis Toolkit pipeline [90]. Variants were filtered by two criteria: read coverage
>50-fold coverage and Phred score >30. The genes with the somatic mutations were predicted in
matched normal colorectal adenoma and tumors using MuTect2 [91]. Genes with somatic mutations
were filtered by the depth coverage >20-fold coverage. Somatic mutation annotation was performed
by Variant Effect Predictor [92]. Default parameters were used in all software analyses.
4.4. CNV Analysis
CNV was identified in matched normal-colorectal adenoma and normal-CRC samples using
“ExomeCNV” [93] in the R package with default parameters. The criteria to identify gain or loss of
copy number variation used absolute log2 of ratios >0.5 [94] with default parameters.
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4.5. The Analysis of Enriched Genes
The analyses of enriched genes in the colorectal adenoma and adenocarcinoma were performed
by the use of genes with somatic mutations in the matched normal-colorectal adenoma and matched
normal-CRC. Enrichr was used to identify the enriched genes and the enrichment pathway [95,96].
4.6. The Genes with Driver Mutation Analysis
The matched normal-colorectal adenoma and matched normal-CRC data were used to identify
genes with driver mutations using the MutSigCV application with the default parameters [17].
4.7. Availability of Data/Materials
The raw data can be found at the Sequence Read Archive (SRA), accession number PRJNA494574.
5. Conclusions
To identify markers for the early detection of CRC, we explored the genetic alterations in six cases
with matched normal colorectal adenoma and five cases with matched normal colorectal adenoma
CRC. We performed whole-exome sequencing and bioinformatic analysis focused on CNV, somatic
mutations, and candidate genes with driver mutations. Our discoveries showed that the gene sets
identified in both matched normal colorectal adenoma and matched normal colorectal adenoma and
the CRC group are involved in the Wnt, p53, and RTK–RAS signaling pathways. It might be used as a
precancerous and early-stage screening marker candidate for CRC.
However, this finding should be validated in a large sample size. One limitation of the current
study is its small sample size, and thus more samples in a larger analysis are required for future studies
to validate our findings.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/7/977/s1,
Figure S1: Data flow of the project, Table S1: Cancer related genes in chromosome 20, Table S2: Somatic mutation
master table, Table S3: Predicted candidate genes with driver mutation.
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